199
Participants
Start Date
December 31, 2007
Primary Completion Date
June 30, 2008
Study Completion Date
June 30, 2008
vabicaserin
This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
risperidone
placebo
Pfizer Investigational Site, New York
Pfizer Investigational Site, Holliswood
Pfizer Investigational Site, Cedarhurst
Pfizer Investigational Site, Philadelphia
Pfizer Investigational Site, Washington D.C.
Pfizer Investigational Site, Rockville
Pfizer Investigational Site, Baltimore
Pfizer Investigational Site, Arlington
Pfizer Investigational Site, Portsmouth
Pfizer Investigational Site, Butner
Pfizer Investigational Site, Hollywood
Pfizer Investigational Site, Aventura
Pfizer Investigational Site, Kissimmee
Pfizer Investigational Site, Indianapolis
Pfizer Investigational Site, Hoffman Estates
Pfizer Investigational Site, Lake Charles
Pfizer Investigational Site, Little Rock
Pfizer Investigational Site, Oklahoma City
Pfizer Investigational Site, DeSoto
Pfizer Investigational Site, Bellaire
Pfizer Investigational Site, Houston
Pfizer Investigational Site, Austin
Pfizer Investigational Site, Austin
Pfizer Investigational Site, Torrance
Pfizer Investigational Site, Cerritos
Pfizer Investigational Site, Glendale
Pfizer Investigational Site, Escondido
Pfizer Investigational Site, San Diego
Pfizer Investigational Site, San Diego
Pfizer Investigational Site, Garden Grove
Pfizer Investigational Site, Hamilton
Pfizer Investigational Site, Willingboro
Pfizer Investigational Site, Kingston
Lead Sponsor
Pfizer
INDUSTRY